Also, high R&D expenses on advanced technologies ... (You can read the full research report on Vertex Pharmaceuticals here >>>) Shares of BK Technologies have outperformed the Zacks Wireless ...

Also, high R&D expenses on advanced technologies ... (You can read the full research report on Vertex Pharmaceuticals here >>>) Shares of BK Technologies have outperformed the Zacks Wireless ...

Also, high R&D expenses on advanced technologies and alternative ... (You can read the full research report on Vertex ...

Sage Therapeutics, Inc. today announced that Chief Executive Officer Barry Greene will discuss the Company's strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference in San ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...